Ablation in Combination With Lenvatinib and Anti-PD-1 Antibodies

Abroad (travel likely)RecruitingPHASE1

Conditions

Hepatocellular Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
Contact: Study coordinator (Haoyuan Yu) · Alexanderyhy@hotmail.com · 13724028868
Contact: Study coordinator (Linsen Ye) · ye_linsen@163.com · 18520788663

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors

Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer) · Pancreatic Ductal Adenocarcinoma (PDAC) · Hepatocellular Carcinoma (HCC)

Abroad (travel likely)RecruitingPHASE1

Beijing, China · Beijing, China

Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells

Solid Tumor (Excluding CNS) · Liver Cell Carcinoma · Malignant Rhabdoid Tumor

Abroad (travel likely)RecruitingPHASE1

Seattle, United States

A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors

CRC (Colorectal Cancer) · Melanoma (Skin Cancer) · HCC - Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE1

Shanghai, China

Hepatic Intra-Arterial Administration of Ipilimumab in Combination With Intra-venous Nivolumab for Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

Abroad (travel likely)RecruitingPHASE1

Villejuif, France